Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia [PDF]
Expert Review of Hematology, 2023 Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer treatment, frequently leading to reduced relative dose intensity, and is associated with reduced survival. Given the lack of FDA-approved therapies for CIT, thrombopoietin receptor agonists (TPO-RAs) have received significant attention for treatment and prevention of CIT ...
Hanny Al-Samkari, Andrew Song
exaly +4 more sources
Chemotherapy‐induced thrombocytopenia in pediatric oncology: Scope of the problem and opportunities for intervention [PDF]
Pediatric Blood and Cancer, 2022 AbstractBackgroundChemotherapy‐induced thrombocytopenia (CIT) is a known hematologic complication of oncology treatment. This single‐institution study examines the degree with which CIT impacts specific pediatric solid tumor cohorts reflected by platelet transfusion burden and treatment modifications.ProcedureData regarding clinically relevant CIT were
Ira Dunkel +2 more
exaly +4 more sources
Disparities in the consensus for treatment of chemotherapy-induced thrombocytopenia. [PDF]
Ecancermedicalscience, 2023 Chemotherapy-induced thrombocytopenia (CIT) is an arduous complication of chemotherapy to be dealt with, and there are many unmet needs in this field to be addressed on the global front. We have conducted this study to contribute to the understanding of existing knowledge gaps of CIT management and highlight the direction to focus future investigations.
Hambardzumyan L +7 more
europepmc +3 more sources
The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China [PDF]
Scientific Reports, 2023 Chemotherapy-related thrombocytopenia (CIT) is a significant adverse event during chemotherapy, which can lead to reduced relative dose intensity, increased risk of serious bleeding and additional medical expenditure.
Shishi Zhou +9 more
doaj +2 more sources
Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis. [PDF]
J Oncol Pharm Pract, 2023 Introduction Chemotherapy-induced thrombocytopenia (CIT) is a significant challenge in cancer treatment, often leading to dose reductions and reduced number of cycles. The limited effectiveness of platelet transfusions in managing CIT highlights the need for alternative treatments.
Gurumurthy G +3 more
europepmc +3 more sources
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. [PDF]
J Clin Oncol, 2019 PURPOSE Chemotherapy-induced thrombocytopenia (CIT) leads to delay or reduction in cancer treatment. There is no approved treatment. METHODS We conducted a phase II randomized trial of romiplostim versus untreated observation in patients with solid tumors with CIT.
Soff GA +12 more
europepmc +3 more sources
Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia? [PDF]
Research and Practice in Thrombosis and HaemostasisChemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy for solid tumors that results in increased bleeding risk and chemotherapy dose reductions, treatment delays, and agent discontinuation.
Hanny Al-Samkari
doaj +2 more sources
Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series. [PDF]
Br J HaematolSummaryManagement of chemotherapy‐induced thrombocytopenia (CIT) is challenging, often resulting in chemotherapy treatment delays, dose reduction, and treatment interruption. Randomized trials support the potential efficacy and safety of thrombopoietin receptor agonists in CIT management.
Galamaga R, Johnston S, Acosta C.
europepmc +3 more sources
Effects of Granules on Chemotherapy-Induced Thrombocytopenia in Gastrointestinal Cancer Patients: A Randomized Controlled Trial [PDF]
Integrative Cancer Therapies, 2019 Background: To observe clinical effects of Shen Cao granules on thrombocytopenia in patients with gastrointestinal cancer undergoing chemotherapy. Patients and Methods: Patients under a FOLFIRI chemotherapy regimen (n = 92) were randomly divided into ...
Chunfeng Yu MS +4 more
doaj +2 more sources
A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia [PDF]
Frontiers in Oncology, 2021 This real-world, observational study aimed to assess and compare the clinical efficacy and safety of eltrombopag with recombinant human thrombopoietin (rhTPO) in the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma.
Qiuhua Zhu +15 more
doaj +2 more sources